European Congress of Clinical Microbiology & Infectious Diseases

European Congress of Clinical Microbiology & Infectious Diseases
April 04-05, 2023
Copenhagen, Denmark

33rd European Congress of Clinical Microbiology & Infectious Diseases.

Explore more information for Gilead COVID-19 therapies
Results (8)

Remdesivir Reduced the Hazard of Hospital Readmission in People With COVID-19 Admitted to the ICU While Delta and Omicron Were the Predominant Circulating Variants

Immunocompromised patients hospitalized for COVID-19 in the United States: evolving patient characteristics and clinical outcomes across emerging variants

Remdesivir reduces readmission in immunocompromised adult patients hospitalised with COVID-19

Remdesivir is associated with lower mortality in cancer patients hospitalized for COVID-19 across emerging variants

Remdesivir is associated with decreased mortality in hospitalized COVID-19 patients requiring high-flow oxygen in the United States

The REDPINE Study: Efficacy and Safety of Remdesivir in People With Moderately and Severely Reduced Kidney Function Hospitalised for COVID-19 Pneumonia

Pharmacokinetics, Safety, and Tolerability of Obeldesivir (OBV; GS-5245) in Healthy Participants

Remdesivir associated with decreased mortality in hospitalized COVID-19 patients. A real-world evidence study using natural language processing